跳至主要内容
临床试验/NCT02837523
NCT02837523撤回不适用

Biomarker for Cystinosis Disease AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL

CENTOGENE GmbH Rostock4 个研究点 分布在 3 个国家开始时间: 2018年8月20日最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
发起方
试验地点
4
主要终点
Development of a new MS-based biomarker for the early and sensitive diagnosis of Cystinosis disease from the blood

研究概览

简要总结

Development of a new mass spectrometry-based biomarker for the early and sensitive diagnosis of Cystinosis disease from the blood

详细描述

Cystinosis is a rare, multisystem genetic disorder characterized by the accumulation of an amino acid called cystine in different tissues and organs of the body including the kidneys, eyes, muscles, liver, pancreas and brain. Generally, Cystinosis is broken down into three different forms known as nephropathic Cystinosis, intermediate Cystinosis and non-nephropathic (or ocular) Cystinosis. Early detection and prompt treatment are critical in slowing the development and progression of symptoms associated with Cystinosis. The kidneys and eyes are the two organs most often affected. Individuals with nephropathic or intermediate Cystinosis ultimately require a kidney transplant. Non-nephropathic Cystinosis only affects the corneas of the eyes. Cystinosis is caused by mutations of the CTNS gene and is inherited as an autosomal recessive disease.

The specific symptoms and severity of Cystinosis vary greatly from one person to another based upon several factors including age of onset and whether the disorder is promptly diagnosed and treated. The progression of the disorder can be slowed by early diagnosis and treatment. Eventually, Cystinosis can affect all tissues of the body. The age of onset for different symptoms varies greatly.

• NEPHROPATHIC CYSTINOSIS (renal Fanconi disease)

Nephropathic Cystinosis is the most frequent and most severe form of Cystinosis. The symptoms of nephropathic Cystinosis usually become apparent within the second half of the first year of life.

Growth failure and renal Fanconi disease are usually the first noticeable complications of the disorder. Although infants appear normal at birth, by the age of one they often fall into the third percentile for height and weight. In addition, affected infants may have episodes of vomiting, poor appetite, and feeding difficulties that contribute (along with kidney dysfunction) to nutritional deficiency and the failure to gain weight and grow at the expected rate (failure to thrive). Ultimately, growth in untreated children with Cystinosis occurs at 60 percent the expected rate.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
2 Months 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Development of a new MS-based biomarker for the early and sensitive diagnosis of Cystinosis disease from the blood

时间窗: 24 months

New methods, like mass-spectrometry give a good chance to characterize specific metabolic alterations in the blood of affected patients that allow diagnosing in the future the disease earlier, with a higher sensitivity and specificity.

次要结局

  • Testing for clinical robustness, specificity and long-term stability of the biomarker(36 months)

研究者

发起方
CENTOGENE GmbH Rostock
申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验